• 中文核心期刊要目总览
  • 中国科技核心期刊
  • 中国科学引文数据库(CSCD)
  • 中国科技论文与引文数据库(CSTPCD)
  • 中国学术期刊文摘数据库(CSAD)
  • 中国学术期刊(网络版)(CNKI)
  • 中文科技期刊数据库
  • 万方数据知识服务平台
  • 中国超星期刊域出版平台
  • 国家科技学术期刊开放平台
  • 荷兰文摘与引文数据库(SCOPUS)
  • 日本科学技术振兴机构数据库(JST)
聂红, 李孔燕, 张晓琦, 冯雪莹, 杨端容, 吴玉斯, 周玖瑶. 2009: 环磷酰胺诱导小鼠血小板减少症模型的建立(英文). 动物学研究, 30(6): 645-652. DOI: 10.3724/SP.J.1141.2009.06645
引用本文: 聂红, 李孔燕, 张晓琦, 冯雪莹, 杨端容, 吴玉斯, 周玖瑶. 2009: 环磷酰胺诱导小鼠血小板减少症模型的建立(英文). 动物学研究, 30(6): 645-652. DOI: 10.3724/SP.J.1141.2009.06645
NIE Hong, LI Kong-yan, ZHANG Xiao-qi, FENG Xue-ying, YANG Dua-rong, WU Yu-si, ZHOU. 2009. Establishment of a Mouse Thrombocytopenia Model Induced by Cyclophosphamide. Zoological Research, 30(6): 645-652. DOI: 10.3724/SP.J.1141.2009.06645
Citation: NIE Hong, LI Kong-yan, ZHANG Xiao-qi, FENG Xue-ying, YANG Dua-rong, WU Yu-si, ZHOU. 2009. Establishment of a Mouse Thrombocytopenia Model Induced by Cyclophosphamide. Zoological Research, 30(6): 645-652. DOI: 10.3724/SP.J.1141.2009.06645

环磷酰胺诱导小鼠血小板减少症模型的建立(英文)

Establishment of a Mouse Thrombocytopenia Model Induced by Cyclophosphamide

  • 摘要: 比较由环磷酰胺两种不同给药方式诱导小鼠血小板减少症模型的效果,并对效果较稳定的一种给药方式进行最佳造模剂量摸索,以期确定一个造模效果较好,毒副作用较低,利于观察治疗药物疗效的血小板减少症模型。模型A组,第1天尾静脉注射环磷酰胺200 mg/kg,然后连续6 d,每天1次以维持剂量30 mg/kg腹腔注射环磷酰胺。模型B组,按150 mg/kg皮下注射环磷酰胺,每天1次,连续3 d。结果显示模型B组造模效果较好,故以模型B组给药方法进行剂量摸索实验。由第7天的血小板计数可知环磷酰胺低(100 mg/kg)、中(120 mg/kg)、高(140 mg/kg)剂量均可引起血小板减少症,而低剂量组与其他组比较有高效低毒的特点,更有利于观察治疗药物的作用,可用于具有升血小板作用药物的药效学研究

     

    Abstract: An experiment was conducted to compare the effects of two mouse thrombocytopenia models induced by cyclophosphamide at two different administration routes to determine a proper cyclophosphamide administration route that could cause stable thrombocytopenia. A suitable drug dosage that could induce thrombocytopenia in mouse efficiently with the definite administration route was then investigated. BALB/c mice were randomly divided into Normal, Model A and Model B groups. To Model A, 200 mg/kg of cyclophosphamide was given by vena caudalis injection as first dose and 30 mg/kg as maintenance dose by intraperitoneal injection at the following 6 days. To Model B, 150 mg/kg of cyclophosphamide was given by subcutaneous injection once a day for consecutive 3 days. All groups were under investigation for 15 days. The result suggested that a decrease in the number of blood platelets of Model B at the 7th day were significantly than that of Normal. Other platelet related indices like platelet distribution width, mean platelet volume and platelet-large cell ratio of Model B increased significantly in comparison with those of Normal group. The platelets count was reduced but fluctuated greatly, and more than half of the mice died in Model A. Therefore, subcutaneous injection of cyclophosphamide for 3 days was used for the cyclophosphamide dosage test. BALB/c mice were randomly divided into Normal, cyclophosphamide low dose (100 mg/kg), medium dose (120 mg/kg) and high dose (140 mg/kg) groups. All groups were under investigation for 11 days. Though all 3 dosages successfully initiated thrombocytopenia as the platelets number dropped at the 7th day, the low dose was considered to be a suitable one that was of high efficacy and low toxicity. Thus, BALB/c mice challenged by subcutaneous injection of cyclophosphamide 100 mg/kg per day for 3 consecutive day is one simple, feasible and stable mouse thrombocytopenia model that could be used for pharmacodynamic test of the drugs which are supposed to have platelets increasing effect.

     

/

返回文章
返回